Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Curcumin in Preventing Gastric Cancer in Patients With Chronic Atrophic Gastritis or Gastric Intestinal Metaplasia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02782949
Recruitment Status : Recruiting
First Posted : May 26, 2016
Last Update Posted : June 13, 2019
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)

Brief Summary:
This randomized phase IIb trial studies how well curcumin works in preventing gastric cancer in patients with chronic atrophic gastritis and/or gastric intestinal metaplasia. Curcumin is an antioxidant compound found in plants that may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Condition or disease Intervention/treatment Phase
Chronic Atrophic Gastritis Helicobacter Pylori Negative Intestinal Metaplasia of Gastric Mucosa Drug: Curcumin Other: Laboratory Biomarker Analysis Other: Placebo Other: Quality-of-Life Assessment Phase 2

Detailed Description:

PRIMARY OBJECTIVES:

I. To compare the change in gastric mucosal interleukin 1beta (IL-1beta) cytokine level, quantified by Luminex assay technology, after a 6-month intervention in participants randomly assigned to the curcumin (Meriva [curcuminoids]) versus placebo arms.

SECONDARY OBJECTIVES:

I. To determine the safety and tolerability of Meriva versus placebo. II. To compare changes in Histology Gastric Score (HGS) from baseline to 6 months for Meriva versus placebo.

III. To compare changes in additional gastric mucosal cytokine/chemokine levels (interleukin 8 [IL-8], tumor necrosis factor-alpha [TNFalpha], and inducible protein 10 [IP-10]; quantified by Luminex assay).

IV. To compare changes in gastric mucosal deoxyribonucleic acid (DNA) damage as assessed by immunohistochemistry (IHC), of the biomarkers 8‐hydroxy‐2'-deoxyguanosine (8‐OHdG) and phosphorylated subtype of histone H2A (H2AX).

V. To explore associations between proinflammatory cytokine genotype status (IL-1beta, IL-8, and TNFalpha single nucleotide polymorphisms [SNPs]; characterized at baseline) and the above outcomes.

OUTLINE: Patients are randomized into 1 of 2 arms.

ARM 1: Patients receive curcumin orally (PO) twice daily (BID) for 180 days in the absence of unacceptable toxicity.

ARM 2: Patients receive placebo PO BID for 180 days in the absence of unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days and 7 months.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: Randomized, Double-Blind, Placebo-Controlled Trial of Meriva® (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
Actual Study Start Date : April 4, 2017
Estimated Primary Completion Date : December 1, 2020
Estimated Study Completion Date : December 1, 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Curcumin

Arm Intervention/treatment
Experimental: Arm I (curcumin)
Patients receive curcumin PO BID for 180 days in the absence of unacceptable toxicity.
Drug: Curcumin
Given PO
Other Names:
  • C.I. 75300
  • C.I. Natural Yellow 3
  • Diferuloylmethane
  • Turmeric Yellow

Other: Laboratory Biomarker Analysis
Correlative studies

Other: Quality-of-Life Assessment
Ancillary studies
Other Name: Quality of Life Assessment

Placebo Comparator: Arm II (placebo)
Patients receive placebo PO BID for 180 days in the absence of unacceptable toxicity.
Other: Laboratory Biomarker Analysis
Correlative studies

Other: Placebo
Given PO
Other Names:
  • placebo therapy
  • PLCB
  • sham therapy

Other: Quality-of-Life Assessment
Ancillary studies
Other Name: Quality of Life Assessment




Primary Outcome Measures :
  1. Absolute change in IL-1beta cytokine levels in the gastric mucosa [ Time Frame: Baseline up to 6 months ]
    Will be measured by Luminex assay. If the data are not normally distributed, the Wilcoxon Rank-Sum test will be used. The 95% confidence intervals will also be provided.


Secondary Outcome Measures :
  1. Incidence of adverse events [ Time Frame: From time of first dose of curcumin up to 7 months ]
    Will be graded by National Cancer Institute Common Terminology Criteria for Adverse Events version 4. The maximum grade for each type of adverse event will be recorded for each participant and frequency tables will be reviewed to determine the overall patterns. The number and severity of adverse events (overall and by intervention group) will be tabulated and summarized.

  2. Change in histology gastric score [ Time Frame: Baseline up to 6 months ]
    Will compare changes in histology gastric score for curcumin versus placebo.

  3. Additional gastric mucosal cytokine/chemokine levels (IL-8, TNFalpha, and IP-10) [ Time Frame: Baseline up to 6 months ]
    Will be quantified with Luminex assay. Changes in the concentrations (or categories) will be explored within and between the intervention arms. Fisher's exact tests, Wilcoxon rank sum tests, and two-sample t-tests will be used to assess differences between groups. McNemar's tests, Wilcoxon signed rank tests, and paired sample t-tests will be used to assess differences within each arm. Graphical methods (i.e. boxplots, scatter plots, etc.) will also be used to describe the data.

  4. Gastric mucosal deoxyribonucleic acid (DNA) damage [ Time Frame: Baseline up to 6 months ]
    Will be assessed by immunohistochemistry. Fisher's exact tests, Wilcoxon rank sum tests, and two-sample t-tests will be used to assess differences between groups. McNemar's tests, Wilcoxon signed rank tests, and paired sample t-tests will be used to assess differences within each arm. Graphical methods (i.e. boxplots, scatter plots, etc.) will also be used to describe the data.


Other Outcome Measures:
  1. Proinflammatory cytokine genotype status (IL-1beta, IL-8, and TNFalpha single nucleotide polymorphisms) [ Time Frame: At baseline ]
    Will be examined in relation to the outcomes above to further characterize the at-risk population and generate hypotheses for future studies.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • PRE-REGISTRATION INCLUSION CRITERIA
  • Ability to understand and the willingness to sign a written informed consent document
  • Willingness to undergo screening tests and procedures
  • Willingness to provide blood and tissue samples for safety/toxicity monitoring and biomarker analyses
  • Willingness to avoid the use of curcumin or any over-the-counter or prescription medications containing curcumin or curcuminoids
  • REGISTRATION/RANDOMIZATION INCLUSION CRITERIA
  • Histologically-confirmed chronic multifocal atrophic gastritis (MAG) and/or gastric intestinal metaplasia (GIM)
  • Helicobacter pylori negative, defined as negative stool antigen testing and negative histological examination
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 1
  • Aspartate transaminase (AST), alanine transferase (ALT) within institutional limits of normal or judged to be not clinically significant by the investigator
  • Alkaline phosphatase within institutional limits of normal or judged to be not clinically significant by the investigator
  • Platelets within institutional limits of normal or judged to be not clinically significant by the investigator
  • Hemoglobin within institutional limits of normal or judged to be not clinically significant by the investigator
  • White blood cells (WBC) within institutional limits of normal or judged to be not clinically significant by the investigator
  • Blood urea nitrogen (BUN) within institutional limits of normal or judged to be not clinically significant by the investigator
  • Total bilirubin within institutional limits of normal or judged to be not clinically significant by the investigator
  • Creatinine within institutional limits of normal or judged to be not clinically significant by the investigator
  • Not pregnant or breast feeding; Note: The effects of Meriva on the developing human fetus at the recommended therapeutic dose are unknown; for this reason, individuals of child‐bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately

Exclusion Criteria:

  • PRE-REGISTRATION EXCLUSION CRITERIA
  • History of other malignancy =< 2 years prior to the registration/randomization evaluation, with the exception of basal cell or squamous cell skin cancer
  • History of colorectal cancer; exception: individuals with stage I or II colorectal cancer who have not received any chemotherapy
  • Known diagnosis of human immunodeficiency virus (HIV); Note: An HIV screening test does not have to be performed to evaluate this criterion
  • History of gastric surgery
  • Receiving any other investigational agents
  • Use of any anticoagulation medications, such as warfarin or Coumadin
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant or breast feeding; Note: Pregnant women are excluded from this study; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with Meriva, breastfeeding should be discontinued if the mother is treated with Meriva
  • REGISTRATION/RANDOMIZATION EXCLUSION CRITERIA
  • Receiving any other investigational, anticoagulation, and/or chemotherapy agents
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to Meriva

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02782949


Locations
Layout table for location information
Honduras
Hospital Regional de Occidente Not yet recruiting
Santa Rosa De Copan, Honduras, 41101
Contact: Ricardo L. Dominguez    504-2-26620107    ricardoleoneldominguez@yahoo.com   
Principal Investigator: Ricardo L. Dominguez         
Puerto Rico
University of Puerto Rico Recruiting
San Juan, Puerto Rico, 00936
Contact: Marcia R. Cruz-Correa    787-772-8300    marcia.cruz1@upr.edu   
Principal Investigator: Marcia R. Cruz-Correa         
Sponsors and Collaborators
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Marcia R Cruz-Correa Mayo Clinic

Layout table for additonal information
Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT02782949     History of Changes
Other Study ID Numbers: NCI-2016-00713
NCI-2016-00713 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
N01-CN-2012-00042
MAY2015-05-01 ( Other Identifier: Mayo Clinic )
MAY2015-05-01 ( Other Identifier: DCP )
N01CN00042 ( U.S. NIH Grant/Contract )
P30CA015083 ( U.S. NIH Grant/Contract )
First Posted: May 26, 2016    Key Record Dates
Last Update Posted: June 13, 2019
Last Verified: June 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Atrophy
Gastritis
Metaplasia
Gastritis, Atrophic
Pathological Conditions, Anatomical
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Stomach Diseases
Pathologic Processes
Curcumin
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action